FDA has approved Dupixent® for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with EoE.
FDA has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to…